Nanogam (Human Normal Immunoglobulin)

Human Normal Immunoglobulin, the active ingredient in Nanogam, is an immunoglobulin presented as a solution for injection for intravenous use. It provides passive immunity by supplying normal human immunoglobulins that bind to and neutralize pathogens and modulate the immune response, helping to prevent infections in patients with antibody deficiencies.

GNH USA supplies Nanogam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide. The company adheres to EU quality standards and offers cold‑chain logistics to ensure product integrity during global distribution.

Nanogam is used in immunoglobulin therapy to replace deficient antibodies across several immune‑related conditions.

- Primary immunodeficiency diseases: restores antibody levels to reduce the frequency and severity of infections. - Secondary immunodeficiency after bone marrow transplantation: provides passive immunity to protect against opportunistic pathogens. - Immune thrombocytopenic purpura (ITP): modulates immune response to increase platelet counts and decrease bleeding risk. - Chronic inflammatory demyelinating polyneuropathy (CIDP): attenuates autoimmune attack on peripheral nerves, improving muscle strength and function.

Intravenous immunoglobulin therapy can be associated with a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache - Fever or chills - Nausea - Fatigue - Infusion‑related erythema or itching - Mild hypertension

Serious or Rare Side Effects: - Anaphylaxis - Thromboembolic events (stroke, myocardial infarction) - Acute renal failure - Aseptic meningitis - Hemolytic anemia - Severe thrombocytopenia

Before initiating Nanogam, clinicians should consider several precautionary measures to minimize risk.

- Assess IgA deficiency: patients with severe IgA deficiency may be at higher risk of anaphylactic reactions. - Monitor renal function: intravenous immunoglobulin can affect kidney perfusion, especially in patients with pre‑existing renal impairment. - Evaluate thrombotic risk: consider history of clotting disorders, as IVIG may increase blood viscosity. - Review cardiovascular status: patients with heart failure should be monitored for fluid overload during infusion. - Pregnancy and lactation: limited safety data; use only if potential benefit justifies potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Human Normal Immunoglobulin may interact with other medicines, altering their effectiveness or safety profile.

Major Interactions (Avoid): - Live vaccines: concurrent administration can diminish vaccine efficacy and increase risk of infection. - Anticoagulants (e.g., warfarin): IVIG may potentiate anticoagulant effect, raising bleeding risk. - Rituximab: may reduce the therapeutic effect of rituximab by providing competing antibodies.

Moderate Interactions (Monitor Closely): - Inactivated vaccines: immune response may be blunted; schedule vaccination appropriately. - Diuretics: monitor renal function and electrolytes due to potential additive renal stress. - ACE inhibitors or ARBs: watch for increased risk of hypertension or renal impairment during infusion.